On Demand Content

Recently Added

Darren testing Ramp

darren testing a ramp upload after security patches

Upload Type: Video Only

Effective engagement through identifying customer needs to build relationships and trust

Julian Spinks General Practitioner Steve Clark Patient Voice and Forum Moderator Beating...

Upload Type: Audio & Slides

Invest internally to develop and nurture talent and create the next generation of digital leaders

Stephanie Bova Head of EUCAN, Takeda Digital Accelerator Takeda

Upload Type: Audio & Slides

Research results on HCPs views and experiences of remote eDetailing as a communication channel

Liz Murray DSenior Director, Integrated Multichannel Engagement Quintiles

Upload Type: Audio & Slides

Commercial

Change your selling model approach to maximise new product introductions

Frank Gehres, Vice President & General Manager, ConvaTec

Upload Type: Audio & Slides

How to sell the value of strategies that utilise KAM and VAS approaches

Andy Davis, Chairman of neoNavitas

Upload Type: Audio & Slides

Formulate win-wins: Positively impact your patient and improve your bottom line through cross-...

Jens Lipinski, Head Patient Relations, Bayer

Upload Type: Audio & Slides

Create ecosystem of care and deliver improved health solutions for patients

Gregory Miller, General Manager, UCB

Upload Type: Audio & Slides

View all Commercial

Market Access

Redefining your Oncology strategy to reflect the reformed landscape

Ana Stojanovska and Nancy Young, both Senior Directors at Xcenda, describe the changing face of...

Upload Type: Audio & Slides

“Title TBC – Real World Introduces Uncertainty…”

Nigel Hughes, Scientific Director, RMEDS, Janssen

Upload Type: Audio & Slides

Biológicos e biossimilares uma analise aprofundada da aprovação, fast-track e intercambialidade

Daniela Marreco Cerqueira, Gerência de Produtos Biológicos, ANVISA

Upload Type: Audio & Slides

Intelligent Pharmaceuticals: providing digital health support to patients

Andy Jones, VP Pharmaceutical Innovation, AstraZeneca

Upload Type: Audio & Slides

View all Market Access

Clinical

From site-centric investigation to patient-centered medical management: Revitalize enrollment by...

Colin Scott, Clinical Trial Leader at Novartis Consumer Health, explains how successful outreach...

Upload Type: Audio & Slides

The Continuing Shifts in the Commercial Oncology Market

Michael Kolodziej, National Medical Director, Oncology Solutions, Aetna

Upload Type: Audio & Slides

Designing protocols while planning for future commercialization

Joe Camardo, Senior Vice President, Celgene

Upload Type: Audio & Slides

How eSource Changes Everything for Sites, Patients and Sponsors

Ed Seguine, CEO, ClinicalInk

Upload Type: Audio & Slides

View all Clinical
Estudio de Caso – LatAm

Sunday, October 2, 2016

Escucha modelos de gestión innovadores implementados por Baxter en el tratamiento de la Enfermedad Renal Crónica, en el beneficio de los pacientes y el uso eficiente de recursos para los sistemas de salud Claudia Brabata Director Market Access & Government Affairs Latin America, Baxter International Inc. Stefano Laganis General Manager – RTS Baxter Colombia

View this webinar
Prove it: Measure and Communicate the Value of Patient Centricity in your Company

Thursday, June 16, 2016

In this webinar Sanofi, Merck, Grünenthal and Roche give their expert insights on how a ‘patients first’ business model not only significantly improves clinical outcomes, but also has a positive impact on profits.

View this webinar
The Access Challenges and its Impact on Pharma's Commercial Teams

Wednesday, June 15, 2016

Integrating access and commercial team’s functions is essential to drive forward commercial success. eyeforpharma bringing you a panel of experts to discuss how to engage and motivate your commercial and access teams.

View this webinar
Patient empowerment: digital communication for improved outcomes

Monday, October 26, 2015

Hear from Morten Hjelmsoe, David Dellamonica, Greg Cohen & Marc Wortmann anddiscover how pharma can support patients while being fully compliant. Understand how digital can heighten patient communication for improved outcomes and uncover new ways to support patient adherence to deliver long-term health benefits.

View this webinar
Stakeholder Perspectives on Patient Adherence

Monday, October 19, 2015

Hear from CSL Behring, Cancer101, Echo Salveo Specialty Pharmacy and EngageRx on how to: Develop standards for defining an effective patient engagement strategy; Recognize opportunities arising in the light of the growing payer and provider interest in manufacturers adherence and patient engagement initiatives; Deliver patient-engagement solutions that incorporate patients and caregivers needs

View this webinar
Optimise New Technologies to Boost Trial Recruitment

Wednesday, October 14, 2015

Hear directly from Sanofi and AstraZeneca on how they are leveraging different technologies to gain participants in their trials,

View this webinar
Personalise your Customer’s Experience

Tuesday, July 14, 2015

M. Bellis, CX Lead Europe, V. Kara, Associate VP of Digital & Multichannel Marketing, Sanofi and M. Hjelmsoe, CEO & Founder

View this webinar
Create the perfect evidence & value proposal for HTAs and Payers

Friday, May 23, 2014

Listen to Barbara Jaszewski, Vice President of Global Pricing and Market Access at Lundbeck, Christelle Saint Sardos, Senior Director of Market Access & Economics at Sanofi Pasteur MSD, and Alexander Natz, Director General of EUCOPE, talk about the need for payers to be engaged in the creation of solutions, and how demand to demonstrate superiority is increasing.

View this webinar
Risk Sharing Q&A Prove the true effectiveness of your medicines and accelerate access

Monday, April 28, 2014

Listen to this Q&A session with Driss Berdaï, Member of the Transparency Committee at the French HAS, Maria Kubin, Vice President of Global Market Access at Bayer, and Alexander Natz, Director General of EUCOPE, who share their advice on how to gain a complete understanding of how to implement a successful Real World Data strategy.

View this webinar
Understand evolving thinking behind clinical pathways

Tuesday, March 25, 2014

Dr. Atul Dhir, CEO of New Century Health, talks about how to incorporate pathway thinking into your development and understand clinical endpoints, and explains how pathways work with payers and physicians and how you can influence the debate.

View this webinar
Improve your offering to your patients with a sophisticated knowledge of patient need

Wednesday, February 19, 2014

Listen to Paul Humphrey, Head of Patient Advocacy at Genzyme, Keir Woods, Director of Oncology at GlaxoSmithKline, and Stephen Head, GP and the Clinical Director of County Health Partnerships for Nottinghamshire NHS Healthcare Trust, explain how to build an accurate picture of your patients and explain how understanding the patient experience can help you achieve meaningful patient centricity.

View this webinar
The next generation of personalized oncology in the US

Wednesday, December 11, 2013

Listen to Laura Housman, Chief Commercial Officera at Molecular Health, and Stan Skrzypczak, Vice President of Business Development at InVitae, share their years of experience in the field to deliver a roadmap to the reimbursement landscape for advanced next-generation sequencing in oncology, and explain how to guarantee that your diagnostic tests evolve with and ahead of dynamic clinical advances

View this webinar
Risk sharing agreements - How to create Real World Data to exceed payers' required outcomes

Tuesday, November 26, 2013

Listen to Nigel Hughes, Global Director of Marketing & Health Information Technology at Janssen Diagnostics BVBA, Craig Richardson, Head of Access to Real World Data at Johnson & Johnson, and Antonio Sarria-Santamera, Director of AETS, discuss how to create Real World Data, and how to maximise patient outcomes and better adherence and uptake by keeping patients at the core of your focus.

View this webinar
Customer Facing Innovation

Friday, November 15, 2013

Listen to David Davidovic, former Vice President and Global Head of Commercial Services at Roche and Genentech, Matt Portch, Vice President of Commercial Model Innovation at Pfizer, and Theo Fellgett, Head of US Operations at eyeforpharma, discuss customer level partnerships, how to achieve customer relationships at a business , and how to increase customer engagement.

View this webinar
Gilead & Model N Webinar: Improve Effectiveness in Global, Regional & Market pricing

Tuesday, November 12, 2013

Listen to Mark Hill from Gilead and James Robinson from Model N zoom in on some key best practices for successful launch sequencing and building a business case for a global pricing improvement program.

View this webinar
Create win-win partnerships with Patient groups

Thursday, October 31, 2013

Listen to Dr. Klaus Suwelack, General Manager of I3g, and Virgil H. Simons, Founder and President of The Prostate Net, talk about a new innovative partnership from I3g - a subsidiary of Janssen - and the needs of the empowered patient, especially the ways in which they are different to those of patients in the past.

View this webinar

Our In-depth Analysis pieces are free to view and download for Freemium and Premium subscribers. Filled with industry-led expertise on a variety of subjects, they all evolve around our core focuses - Sales/ Marketing, Digital, Patients, Market Access/Evidence and Clinical Trials.

The Great DTC Shake-Up

This in-depth eyeforpharma whitepaper, which we developed with Health Perspectives Group explores the evolving role of DTC advertising with direct feedback from patient’s - including exclusive results from the recent “DTC Attitudes, Behaviours and Preferences” patient study conducted by Health Stories Project – Insights, (HSPi).

Trends in Market Access

In the current healthcare climate, pharma must ensure all routes to access are covered, with seamless evidence plans ready for HTA, and intelligent pricing schemes for maximum reimbursement.

We interviewed experts to bring you the tried-and-tested techniques you’ll need to get access and reimbursement: 

GSK's new 'ethical' customer approach: Is it delivering?

GSK’s move to a new model of customer engagement has generated a great deal of debate. Indeed, many commentators remain skeptical that this ‘ethical’ model – especially the decoupling of sales incentives from prescription volume isn’t robust enough to deliver results in the long-term.

Will GSK’s new transparent, reputation-boosting sales model be a template for the entire industry? 

Trends in Real-World Evidence

The health economy is changing quickly, moving from measuring inputs to outputs. When reward is based on an outcome it becomes an incentive to do everything possible for customers and patients.

This is what ‘from volume to value’ means; a move from doing the minimum to the maximum, for patients. Nowhere do we see the move from volume to value more clearly than in the growth in the importance of RWE.

In this latest thought piece, eyeforpharma explores the power of RWE to transform the understanding of patients, treatments, outcomes and costs.  

Trends in Patient-Led Clinical Trials

Find out about the current challenges in clinical trials, and how to overcome these.

In our interviews with Craig Lipset, Head of Clinical Innovation, Pfizer, Jeanne Hecht, COO of Median Technologies, and Jennifer Byrne, CEO of PMG Research, we ask: what barriers and myths deter physicians from discussing clinical trials and patients from participating in them? How can patient education be used to emphasise the “white glove” treatment patients receive while part of a trial?

Goodbye, sales and marketing. Hello, integrated Commercial team!

What does the future hold for commercial...?

This in-depth eyeforpharma whitepaper will explore how pharma is integrating customer-facing teams in order to become more customer-centric.

The aim? To avoid duplication and ensure consistency of approach across a number of stakeholders. 

This paper explores:
- The drivers behind these trends (the problem)
- The wider benefits of greater customer-centricity (the solution)
- How companies are changing internally to realise this vision
- The challenges of greater integration
- The roles and skillsets within integrated commercial teams
- The impact on customers
- The future of the commercial team

Trends in Medical Affairs

In this magazine, we sit down with Dr Ameet Nathwani, CMO at Sanofi to discuss the burgeoning role of medical affairs and the need for continuous, cost-effective evidence generation. We explore why MSLs need to get in touch with their emotions to engage with impact and we delve into the changing face of medical affairs as it's set to become a fully-fledged strategic partner…

Trends in Clinical Data & Technology

Whilst it seemed a long, hard slog, in the last decade or so, the paradigm for clinical trials has flipped almost entirely from paper to electronic data collection. But why stop there, now that most of the infrastructure is in place to make third generation trials a reality?

We have spoke to leading industry figures really casting vision in the clinical space to discuss innovative approaches to data and technology, covering the most important opportunities available such as site-less / direct-to-patient clinical trials, paperless trials and patient-centricity that you can measure.  

What Pharma Can Learn From Patients

A Global Patient Advocate Survey

Pharma want to engage with patients, but it is still not clear when and how this should happen. The struggle to attract and retain patients to clinical trials remains one of the major challenges in the drug development process.

MK&A and eyeforpharma surveyed a range of global patient advocacy groups and you can see the results and discussion of the outcomes in this whitepaper. 

The Whitepaper contains discussions of the survey findings from;
- Jeff Sherman, CMO, Horizon Pharma
- Jeanne Regnante, Executive Director, Head, Patient engagemeent strategy office, Office of the CPO, Merck & Co, Inc
- John Whyte, Director, Professional Affairs and Stakeholder Engagement, FDA
- Jane Reese-Coulbourne, Senior Consultant, MK&A

Patient Centricity vs. Profitability - why commercial innovation is key

Beyond a few organisations where entire teams and roles have been created around the pursuit of true 'patient centricity', some of pharma's most important customer-facing functions are unclear on the necessary steps needed to be worthy of the title 'patient-centric' - and even whether or not it should be their objective at all. 

Highlights of the whitepaper include:

- Can patient-centricity and profitability co-exist? We have the answer.
- We ask industry experts about finding the 'sweet spot' where there can be both patient focus and business focus - and the needs of both are met
- Pharma have confidence in the commercial benefirts of patient focus, but lack the confidence to take thinks to the next level. We explore what is needed to make this happen.
- How to make patient focus and business focus real - throught budget, measurement, and training.
- Concrete examples of the role of patient focus on profitability. 

Key Contributors:

- Christi Shaw, former U.s. Country Head and President, Novartis Pharmaceuticals Corporation
- Ramona Sequeira, President, Takeda Pharmaceutical Company Ltd
- John Gerow, Service Team Strategy Partner, Ashfield & Principle, JG Consulting Inc.
- Deborah Waterhouse, SVP and Business Unit Head UD Primary Care, GSK
- Jens Lipinski, Head of Patient Relations, Bayer Healthcare

Customer Experience and Beyond: Why Digital Changes Everything

We spoke to some of the most respected names in the industry, including:

- Gerhard Arnhofer, Vice President, Head of Integrated Multichannel Marketing CoE, Bayer
- Tim White, Head of Customer Experience, Teva
- Panos Papakonstantinou, Head Digital Commercial, Europe, Novartis
- Monique Levy, SVP, PatientsLikeMe
- Jessica Federer, Chief Digital Officer, Bayer
- Hicham Naim, Strategy & Customer Centricity Europe and Canada, Takeda

… to find out why pharma has been so slow in properly implementing multichannel and how we can catch up with industries such as banking, retail and airlines.

Discussing topics such as digital transformation, change management and customer experience this white paper will give you all you need to know to perfect your multichannel strategy and build stronger relationships with your key customers. 

Advancing Patient Recruitment & Engagement in Clinical Trials

This whitepaper highlights some of the most advanced companies in their innovative approaches to trial recruitment. Witness first-hand 5 case study examples of how the industry is reshaping its ways to overcome the recruitment battle.

Hear from:

- EMD Serono: Paulo Moreira, Vice President, Global Clinical Operations, External Innovation and Tanja Keiper, Associate Director share their restructure to support recruitment
-Lilly: Robert Kroes, Clinical Innovation Consultant shares his successes with a user friendly approach to trial education
- NIHR: Matt Cooper, Business Development & Marketing Director shares how they were recruiting so quickly within the UK , they were asked to stop to allow other countries to catch up
- The AKU Society: Oliver Timmis, CEO shares how pharma can benefit from collaborative recruitment techniques to achieve a 1 in 2 recruitment result.
- Pfizer: Craig Lipset, Head of Clinical Innovation shares his unique approach to engaging and listening to patients digitally 

Aligning cost with value in oncology

In 2016 our webinar "Demonstrating Value in Price" provided discussion around a plethora of vital questions on pricing & value frameworks. In response, we've developed a paper compiling industry research, top insights for the webinar, and exclusive interviews. 

Contributors include:
 - Mike Kolodziej, National Medical Director, Aetna
- Scott Shortenhaus, Director Oncology, Professional Relations, Advocacy, & Policy, Eli Lilly
- Anna Forsythe, Head of Global Value & Access, Eisai
- Steven Paulson, CEO, Texas Oncology
- Jack Whelan, Cancer Warrior

Quality Risk-Based Management by Design

We recently sat down with Brian Nugent, Associate Director, ClinOps Process at Gilead Sciences. He shared his experience with designing a successful framework on how QbD (Quality by Design) can be integrated into the risk mitigation management model and how to realize an optimal return from RBM (Risk Based Monitoring).

Gain these insights and get your copy now

Finding the Hidden Message in your Data

The emergence of the Internet was a phenomenon but what we didn’t foresee was the diverse and large amounts of electronic health data it generated. This has been overwhelming and close to impossible to manage with traditional data management tools and systems.

  1.  What analytics do we use in the analysis of different types of data?

  2.  What are the weaknesses of the data captured?

  3.  How do we establish the reliability and validity of different data sets?

To answer to these questions we have developed a new white paper: “What is your data telling you: Finding the hidden message in your data”

Patient-Centred Culture by Design

Embedding patient-centred focus into the culture of pharmaceutical organisations. 

Big pharma claim their long term goal is to embed a patient-centred culture across their organisation – but how can they undertake such a fundamental change considering their complexity, size and resistance to change?

Key topics addressed include:

- Organisational change: Reinforce new systems, align internal structures and encourage cross-collaboration
- Talent: Hire and train your workforce to adopt new behaviours, competencies and attributes
- Return on investment: identify specific KPIs to identify patient-centred results and impacts on your business

KAM Prescription for Commercial Success

As cost pressures continue to rise and the decision-making power shifts from physicians to a broader range of stakeholders, leading pharma companies are actively switching to key account management to develop lasting value partnerships with the evolving customer base.

Download eyeforpharma’s new whitepaper featuring first-hand insights from Key Account Managers at Daiichi Sankyo, Lilly USA, Pfizer, Eisai, Alcon and Shire.

Find out more about:

- New models of engagement
- The true meaning of the KAM role
- Organizational and structural implications

Artificial Intelligence: A Brave New World for Pharma

Now, with the advent of ‘big data,’ companies are harnessing the power of AI to deliver more focused solutions in a variety of areas; AI helps them understand data in real-time. In a recent interview, Dr Andree Bates, President of Eularis, agreed to share some thoughts on how AI can be applied to the pharmaceutical industry to help reduce trial time, crunch data, and facilitate healing.

Future Signs: Trends that will Shape the Future of Healthcare

"Future Signs" provides an illuminating round-up of the technologies and trends that will shape the future of healthcare.

In order to remain relevant, pharma's role will need to change to reflect the technological improvements, societal expectations and medical improvements Mesko predicts.

In this overview, you will read about:

- Some of the disruptive innovations that will allow patients to become the pilots of their own health

- The practical and ethical challenges this new technology brings e.g. healthcare will become more predictive

- The need for pharma's role to change with enhanced communication between pharma and patients becoming vital

- The need to embrace technology in order to deliver highly customized options

The 7th Era of Marketing: Content-Driven Experiences

Content is essential but the key is how this strategy can be integrated into your marketing and customer plans across the business.

This paper covers: 

- How patient experience is driving marketing and how pharma can respond

- Content is not an end in itself: understand exactly who your customers are and what they want

- Create a story with heart and instil brand consistency

 

Bridging the Diversity Gap in Clinical Trials

People from racial and cultural minorities are not effectively targeted by trial recruiters for clinical studies. This gap can lead to sub-optimal development of new medicines and can further disparities in health outcomes among racial and cultural groups.

To understand the importance of bridging the diversity gap, we sat down with Melva Covington, Director, Global Evidence and Value Development at Sanofi. She shared her experience with clinical trials that include patients from diverse, under-represented backgrounds in pharmaceutical research.

Inspirational Leaders in CX: 3 Case Studies from the Multichannel Customer Experience Conference 2015

We have put together an exclusive report summarising the key Case Studies from Multichannel Customer Experience 2015 - great to share amongst those who couldn’t join us along with those who were there.

- Hear from three out-of-industry Customer Experience experts who share their experiences of how they instigated culture change to engage their employees and transform into highly focused, customer-oriented organisations that could deliver a highly efficient customer experience.

- Understand your audience and who you’re for. Use data to draw out fundamental needs. Invest in tools which will help you understand customer behaviour.

- Really understand what you’re for, your purpose and communicate it.

„- Reach your audience in new and unexpected ways with engaging, powerful stories that form an emotional connection.

„- Measure: keep a rigorous eye on what’s working and what’s not.

Data & Technology in Clinical Trials 2015

Teaming up with Eli Lilly and DrugDev Advisory Board, eyeforpharma conducted a 'State of the Industry' survey to investigate how pharma is currently leveraging data and technology and how this will change over the next 2 years.

Highlights include:

- Adopt a risk based approach for a cheaper way to clean your data, ensure optimum data quality and patient safety

- Integrate real world and real time data for faster data generation, to quickly demonstrate value to patients and find urgent answers to unmet needs

- Overcome rising R&D costs by utilising big data to identify patient sub groups, integrate patients into research stages to better identify new biomarkers and provide more personalised treatments

- See how mobile and wearable devices encourage patient participation by virtualising parts of trials, reduce patient burden and enhance data quality

Your Customer is in Charge; Barcelona 2015 Conference Highlights

We have put together an exclusive report summarising the key takeaways from Barcelona 2015 - great to share amongst those who couldn’t join us along with those who were there. 

Take another look at how:

- Our C-suite panel reinforce a patient-centric culture with a drive for personalised healthcare and external partnerships

- VPs from BI, Merck, Ferring, CSL Behring and UCB are embedding the patient voice in their own organisation

- Digital technology is transforming the way we engage with our customers and revolutionising our sales force

- Key conclusions, critical learning and exclusive polling results from Europe’s largest commercial pharma gathering

"We Need to Talk": Achieving Market Access in South Africa

Achieving commercial success has proven difficult due to inflexible pricing legislations, non-standard dossier requirements, unclear guidelines, and restricted formulary access by prescribers.

9 industry experts partnered with eyeforpharma to help understand the current environment and how to move healthcare in South Africa in the right direction.

The whitepaper delves into:

- The current situation between payers and pharma
- How the public and private sectors are changing
- Private v public market - does pharma really have to make a choice?
- Physician and patient perspectives
- How to build a mutually respected and valued relationship
- How pharma can regain trust with other stakeholder groups

Market Access & Pricing Excellence. Real World Evidence Europe 2015 Highlights

Market Access & Pricing Excellence 2015, co-located in Amsterdam with Real World Evidence Europe, gave key players the opportunity to discuss the future funding of innovative pharmaceuticals, approaches to incorporating real world evidence (RWE) into product development, and challenges associated with the growing body of patient data collected with the help of mobile devices. 

Download to find out what happened at this year's event.

The Voice of the Organized Customer

The Voice of the Organized Customer

Pharma’s Opportunity to Meet the Needs of Health Systems in a Shifting Healthcare Landscape

The majority of pharma’s current go to market strategies does not achieve the expected results. It is pivotal to develop and execute B2B programs based on a validated commercial effectiveness model that meets customer needs.

Are you ready to partner with health systems and IDNs?  We've partnered with The Kinetix Group and surveyed health system leaders for a new strategy briefing.

This 20-page briefing has been written to show you:

- The shifting site of care landscape with new analytics and EMR systems, the increasing role of the consumer and rapid consolidation - what does it mean for your go-to market model?
- Six detailed case studies that illustrate pharma’s opportunity to lead the change and collaborate
- What you can do through enhancement of field team credibility, population health management, patient engagement through customizable solutions, and utilizing the patient journey.

HCPs: "We want Partnerships with Pharma"

What can pharma do to improve patient care? eyeforpharma along with M3 Europe asked 549 European healthcare providers questions provided by pharma execs.

We then analysed the results and got senior level execs from Boehringer-Ingelheim, M3 Europe and AbbVie to comment. These were some of the results:
- How pharma can help to improve patient care and support
- How HCPs would operate if they were in your shoes
- The perception HCPs have about pharma companies and why
- The thoughts of hundreds of HCPs in one place

 

Adjusting to a New Reality: Progressing Patient-Centricity. The Patient Summit 2015 Highlights

 
The Patient Summit conference is now in its twelfth year, and during that time
the concept of a patient-focused pharmaceutical industry has become a reality.
From a slow start as a microtrend pioneered by the more innovative companies,
the patient voice can now be heard at every step of the decision-making process. 
 
Download to find out what happened at this year's event.

Predicting Patient Interest and Participation in Clinical Trials: What Really Matters?

Find out which patient characteristics REALLY influence interest & participation in clinical trials.

In this report, you’ll discover:

- Common characteristics of chronic disease patients who participate in clinical research studies
- How factors like gender, physician satisfaction, treatment experiences, and concerns about financial costs impact patient interest and participation in trials
- Implications for attracting the most interested and engaged patients in recruitment programs.

Patient-Centered Drug Development- A Roadmap for Pharmaceutical Leaders

Putting patients at the center of the clinical trial has the potential to make the development process radically more effective. I am sure you heard the “Why”. Now let’s turn the discussion to the “How”.

To give you some guidance, eyeforpharma, with the contribution of the industry’s top thought leaders, has answers to your question by publishing the stakeholder handbook “The Patient- Centered Drug Development- a Roadmap for Pharmaceutical Leaders”

How is pharma tackling non-adherence?

Non-adherence to medication causes problems for patients, healthcare providers, payers and pharma companies. It impacts Pharma by reducing revenues and undermining payer and prescriber confidence in the effectiveness of the brand. S3 group teamed up with eyeforpharma to survey over 200 healthcare professionals to study the extent and scale of the issue and to understand the initiatives, structures, objectives and practices the Pharma industry is putting in place to tackle it.

Payers’ Forum, Europe Summit, 2014, Highlights Report Partnering with Payers to Deliver Value

Download this 13 page report and learn about:

- Homogenization of HTA processes in Europe
- Value-based pricing 
- Pharmaceutical Price Regulatory Scheme 
- Putting together a perfect dossier for the German market 
- Strategy needs for centralized and decentralized countries

The Patients Summit 2014: Highlights Report - Adding colour to the picture

 
- Insights into how the Patient Opinion Leader is driving change in pharma
- Examples of what a real patient-centric organisation looks like
- Videos of interviews with key speakers including Keir Woods, Director Oncology GSK and Jack Whelan, Cancer survivor.
 

The Future of Clinical Trials: How Bringing Patients To The Centre Can Cut Costs And Deliver Better Outcomes

Merck Serono, Sanofi, Quintiles and Amgen share their views on patient centricity in clinical trials.
 
In the white paper, you'll find out how pharma companies are genuinely building trials that fit in with patients' lives and re-focusing their efforts on patient outcomes. They talk about the benefits of patient centricity and the challenges they're working to overcome. You'll also get exclusive insights into how these companies have been organising their business around the patient and get tips on where you should focus on the future.

The Future of the U.S. Oncology Market: Preparing for Healthcare 2.0

This 15-page report presents cross-industry analysis on reimbursement and market access strategies designed to help you:

  • Overcome barriers to traditional premium pricing
  • Re-align stakeholder partnerships in the context of evidence-based care and clinical pathways
  • Leverage risk-sharing agreements as a mechanism of market access in the US
  • Achieve favorable reimbursement through ECV differentiation and value added services
  • Prepare for demands around companion diagnostics

Real world evidence and digital healthcare: The next frontier

This  15-page report looks at Pharma's biggest opportunities for the future, including:

  • A new frontier of innovation
  • Smartphone penetration: The power of numbers
  • The challenges of data collection and design of wearables
  • Key takeaways for Device Design
  • Looking to the future

Razing Silos to Enhance Collaboration

Developing an organization that drives value, wellness and integrated care

This 14 page paper will help you to:

  • Gain insights into what industry leaders such as Merck, Pfizer & GSK are doing to enhance collaboration
  • Drive more effective cross-functional collaboration through an understanding of the key ingredients for success
     

Executive Briefing on ORAL ONCOLYTICS

The 16 page whitepaper includes:

  • Understand the realities and trade-offs for oral therapeutics

  • Strategic perspectives and pharma case examples

  • Learn about the next frontier of new agents

The Patient-Centered Clinical Trial (PCCT): How to Achieve the Organizational Change Needed

The 15-page whitepaper provides insight into:

  • Practical examples and executive action points to realize the PCCT in each dimension

  • Case studies from 19 senior clinical trial leaders from Eli Lilly, Genzyme, National Breast Cancer Coalition, CTTI, PCORI, UCB, Cancer Treatment Centers of America, Michael J. Fox Foundation and many others

Blackdot: Bridging The Gap

Understand the critical role of the First-Line Sales Manager in Re-focusing the Frontline Sales Effort.

This whitepaper will provide insight into:

  • How performance profiling can enable better, more tailored individual management

  • How to achieve total buy-in to your segmentation, targeting, and sales model

  • Which processes drive effective communication that enable organisational clarity and high-performing sales teams

Market Access England: Navigate the Value Chain

Although England accounts for no more than 3% of global pharma sales, it is, alongside Germany, the most externally referenced country in Europe in relation to drug pricing. However, recent structural reforms to the NHS and NICE have complicated an already difficult market access approach.

This exclusive whitepaper aims to simplify these changes and offer you clear guidance on a new model of market access in this crucial European market.

From Dinosaur to Digital: How Smart Technology is Transforming Pharma Sales

Discover the impact for your role during times of digital advancements by downloading your 18 page whitepaper.

Your copy will include:

  • 7 case studies on how digital is affecting sales

  • Insights from Actelion, MHI Global, Boehringer Ingelheim, UCB, LEO, Treato and Astellas

  • Evidence that if your company provides better customer experience you will perform better financially

Value-Added Services Summit 2014: Highlights Report

Partners in Integrated Healthcare: Evolving to a Solutions-Based Model.

Download this 14 page report to:

  • Find out what the trends in integrated care in European pharma are

  • Learn about how Sanofi, Janssen and MSD are doing to build value added services

Payer’s Forum Highlights eBook

Partnering with Payers to Deliver Value.

Download this 18 page eBook to gather insights from:

  • Alexander Natz, Director General, EUCOPE

  • Oriol Solà-Morales, Former Director of HTA assessment, Catalan Agency HTA

  • Thomas Schael, CEO and Commissioner, Local Health Authority, Naples

Leveraging the mHealth Opportunity

  • Be inspired by 6 pioneers of mHealth and how they have developed mobile health apps

  • Gain insights into the key trends in mhealth

  • Understand how to leverage mHealth opportunities and drive value for HCPs, payers and patients

Value-Added Services Case Study Overview

A step-by-step guide to the imagination and implementation of value-added services in pharma, with case studies from Janssen Healthcare Innovation, Pfizer Integrated Health, MSD, Eli Lilly and NICE. It’s not an exact science, but our interviewees have enough real experience between them to help guide you on your way.

The Industry Healthcheck: Results

Download the results from this year's Healthcheck survey complete with commentary from industry thought leaders and find out what 1600 senior pharma executives from around the globe thought about:

  • The state of trust and reputation in the pharma industry

  • The strategic direction of the industry

  • How payers are changing the pharma sales environment

  • How pharma sees healthcare reform impacting the industry

Barcelona 2014

This 15 page report will provide you with:

  • Practical steps on how to drive digital success from Boehringer Ingelheim

  • Insights from UCB on how to transform into a patient-centric organisation

  • Foresight into how the changing payment model will impact your business from RAND

  • An example of how Pfizer US moved from volume to value

Multichannel: Time for Implementation

How to overcome the biggest challenges that hinder multichannel marketing implementation.

  • What you need to get your team and the organisation up to speed for implementation success

  • Practical steps on how to gain the support from leaders and functions including IT, communications and sales

  • Insights from experts on what you need to do to ensure compliance and how to develop the right approval process

Give Your Mobile App A Clean Bill Of Health

As the marketplace floods with medical apps for mobile devices, bringing patients directly in contact with app developers who may not be accustomed to handling sensitive health information. In addition to the fast growing number of savvy app users and perceptive authorities, it is becoming crucial that you ensure that your mobile app is in line with data protection best practice.

The Pharmacist: Tomorrow’s Stakeholder

As the pharmacist is becoming a more integral stakeholder in a patient’s decision making process. It is imperative that pharma companies understand the market dynamics shaping up the pharmacy industry. Cedric Pantaleon, GSK, reveals that engaging pharmacists to boost adherence to complex drug regimens is revolutionary in the pharmacy channel. The increasing pace of the change suggests that there is a demand to adjust current models.

Implementing CLM

The benefits of CLM are numerous and well known, however there's one topic rarely touched upon - once you've made the decision to go CLM, how do you implement it?

Innovation: From Concept to Reality

In today's world of technological marvels, it's never been a better time to be a pioneer, a disruptor, an innovator. However despite our 21st century appetite for pushing boundaries, it's often still a challenge to grow and nurture these ideas in established companies.

Featuring interviews and insights from some of the industry's most creative marketers, our constructive guide will help YOU sell your innovative idea!

Sales Best Practice

Of all the business functions in pharma, sales are perhaps experiencing the greatest change.

Discover what practices your sales teams need to be employing and the latest sales management techniques being used by industry leaders in our comprehensive guide.

The True Value of Telehealth

Telehealth is gathering support as a cost-effective tool to help deliver sweeping improvements in healthcare. There is much debate however as to whether it improves quality of life or isolates the patient and whether it is an affordable addition to the patient care toolbox.

The True Value of Telehealth examines the case for inclusion, honestly confronting arguements against and clarifying the measures and expectationsyou need for a successful telehealth approach to patient care.

The Patient Communication Opportunity

The opportunities for effective patient communication have never been so numerous or so important. We've put together a little guide designed to demonstrate where putting time and resources is likely to have the greatest positive impact for the patient and for the industry.

The Importance of Patient Services

It is increasingly apparent that the pharma industry has a role to play in patient support. While traditional communication efforts have been focused on increasing prescriptions, the reality is that those prescriptions are not delivering the benefits they should to patients. In return, non-adherence patients are costing the industry billions of dollars every year.

This paper focusses on the positive effect that patient services can have on adherence, to the benefit of the patient and the industry.

The Accountable Care Organization

The Accountable Care Organisation is the most ambiguous of the new entities borne of the Affordable Care Act - however, an understanding of the principles of engagement with this trailblazing new institution is crucial to successful navigation of the US oncology landscape.

Emerging Markets: The Second Tier

eyeforpharma has spoken to innovative industry experts and offers you this exclusive guide to ensure permanence and sustainability in some of the fastest growing markets in the world.

Featuring business intelligence and regional insights on Indonesia, Pakistan, Ukraine, Thailand and Vietnam.

Show Me The Evidence

Payers are now a significant player in product commercialization and companies need to rethink their business models.

In this whitepaper we hear directly from G5 European Payers on there needs and expectations of the industry when bringing drugs to market.

Real World Data: Sources and Applications

Expert guidance on the benefits and sources of real world data. An overview of the disruption RWD will cause to R&D, clinical outcomes and market access.

Oncology Reimbursement

As demand rises and budgets constrict across the continent, reimbursement for Oncology drugs has become a significant challenge for European pharma. What has become clear is that developing a market access strategy on a country-by-country basis is key.

We've commissioned this paper to analyze how Germany, UK and Spain have developed, providing insightful models for your reimbursement approach across the rest of the continent.

Personalized Medicine in Oncology

Advancements in Personalized Medicine claim to deliver better efficacy, better outcomes and better value... But can personalized medicine actually deliver on this promise?

Understand the true impact of personalized medicine on your stakeholders.

Patient-Focused Drug Development - Fact, or Fiction?

This 30-page paper covers:

  • Exclusive insights from leading pharma, incl. Eli Lilly, Pfizer, Novartis, Genentech, Shire, Janssen and J&J on how to leverage innovation in drug development

  • A step-by-step reflection on how to achieve the benefits of ePRO (electronic patient-reported outcomes)

  • An understanding of novel approaches to write protocols and plan recruitment strategies based upon individual patient needs

Trends in Patient-Led Clinical Trials

Find out about the current challenges in clinical trials, and how to overcome these.

In our interviews with Craig Lipset, Head of Clinical Innovation, Pfizer, Jeanne Hecht, COO of Median Technologies, and Jennifer Byrne, CEO of PMG Research, we ask: what barriers and myths deter physicians from discussing clinical trials and patients from participating in them? How can patient education be used to emphasise the “white glove” treatment patients receive while part of a trial?

Trends in Clinical Data & Technology

Whilst it seemed a long, hard slog, in the last decade or so, the paradigm for clinical trials has flipped almost entirely from paper to electronic data collection. But why stop there, now that most of the infrastructure is in place to make third generation trials a reality?

We have spoke to leading industry figures really casting vision in the clinical space to discuss innovative approaches to data and technology, covering the most important opportunities available such as site-less / direct-to-patient clinical trials, paperless trials and patient-centricity that you can measure.  

Advancing Patient Recruitment & Engagement in Clinical Trials

This whitepaper highlights some of the most advanced companies in their innovative approaches to trial recruitment. Witness first-hand 5 case study examples of how the industry is reshaping its ways to overcome the recruitment battle.

Hear from:

- EMD Serono: Paulo Moreira, Vice President, Global Clinical Operations, External Innovation and Tanja Keiper, Associate Director share their restructure to support recruitment
-Lilly: Robert Kroes, Clinical Innovation Consultant shares his successes with a user friendly approach to trial education
- NIHR: Matt Cooper, Business Development & Marketing Director shares how they were recruiting so quickly within the UK , they were asked to stop to allow other countries to catch up
- The AKU Society: Oliver Timmis, CEO shares how pharma can benefit from collaborative recruitment techniques to achieve a 1 in 2 recruitment result.
- Pfizer: Craig Lipset, Head of Clinical Innovation shares his unique approach to engaging and listening to patients digitally 

Finding the Hidden Message in your Data

The emergence of the Internet was a phenomenon but what we didn’t foresee was the diverse and large amounts of electronic health data it generated. This has been overwhelming and close to impossible to manage with traditional data management tools and systems.

  1.  What analytics do we use in the analysis of different types of data?

  2.  What are the weaknesses of the data captured?

  3.  How do we establish the reliability and validity of different data sets?

To answer to these questions we have developed a new white paper: “What is your data telling you: Finding the hidden message in your data”

Bridging the Diversity Gap in Clinical Trials

People from racial and cultural minorities are not effectively targeted by trial recruiters for clinical studies. This gap can lead to sub-optimal development of new medicines and can further disparities in health outcomes among racial and cultural groups.

To understand the importance of bridging the diversity gap, we sat down with Melva Covington, Director, Global Evidence and Value Development at Sanofi. She shared her experience with clinical trials that include patients from diverse, under-represented backgrounds in pharmaceutical research.

Data & Technology in Clinical Trials 2015

Teaming up with Eli Lilly and DrugDev Advisory Board, eyeforpharma conducted a 'State of the Industry' survey to investigate how pharma is currently leveraging data and technology and how this will change over the next 2 years.

Highlights include:

- Adopt a risk based approach for a cheaper way to clean your data, ensure optimum data quality and patient safety

- Integrate real world and real time data for faster data generation, to quickly demonstrate value to patients and find urgent answers to unmet needs

- Overcome rising R&D costs by utilising big data to identify patient sub groups, integrate patients into research stages to better identify new biomarkers and provide more personalised treatments

- See how mobile and wearable devices encourage patient participation by virtualising parts of trials, reduce patient burden and enhance data quality

Predicting Patient Interest and Participation in Clinical Trials: What Really Matters?

Find out which patient characteristics REALLY influence interest & participation in clinical trials.

In this report, you’ll discover:

- Common characteristics of chronic disease patients who participate in clinical research studies
- How factors like gender, physician satisfaction, treatment experiences, and concerns about financial costs impact patient interest and participation in trials
- Implications for attracting the most interested and engaged patients in recruitment programs.

Patient-Centered Drug Development- A Roadmap for Pharmaceutical Leaders

Putting patients at the center of the clinical trial has the potential to make the development process radically more effective. I am sure you heard the “Why”. Now let’s turn the discussion to the “How”.

To give you some guidance, eyeforpharma, with the contribution of the industry’s top thought leaders, has answers to your question by publishing the stakeholder handbook “The Patient- Centered Drug Development- a Roadmap for Pharmaceutical Leaders”

The Future of Clinical Trials: How Bringing Patients To The Centre Can Cut Costs And Deliver Better Outcomes

Merck Serono, Sanofi, Quintiles and Amgen share their views on patient centricity in clinical trials.
 
In the white paper, you'll find out how pharma companies are genuinely building trials that fit in with patients' lives and re-focusing their efforts on patient outcomes. They talk about the benefits of patient centricity and the challenges they're working to overcome. You'll also get exclusive insights into how these companies have been organising their business around the patient and get tips on where you should focus on the future.

The Patient-Centered Clinical Trial (PCCT): How to Achieve the Organizational Change Needed

The 15-page whitepaper provides insight into:

  • Practical examples and executive action points to realize the PCCT in each dimension

  • Case studies from 19 senior clinical trial leaders from Eli Lilly, Genzyme, National Breast Cancer Coalition, CTTI, PCORI, UCB, Cancer Treatment Centers of America, Michael J. Fox Foundation and many others

Patient-Focused Drug Development - Fact, or Fiction?

This 30-page paper covers:

  • Exclusive insights from leading pharma, incl. Eli Lilly, Pfizer, Novartis, Genentech, Shire, Janssen and J&J on how to leverage innovation in drug development

  • A step-by-step reflection on how to achieve the benefits of ePRO (electronic patient-reported outcomes)

  • An understanding of novel approaches to write protocols and plan recruitment strategies based upon individual patient needs

Trends in Market Access

In the current healthcare climate, pharma must ensure all routes to access are covered, with seamless evidence plans ready for HTA, and intelligent pricing schemes for maximum reimbursement.

We interviewed experts to bring you the tried-and-tested techniques you’ll need to get access and reimbursement: 

Trends in Real-World Evidence

The health economy is changing quickly, moving from measuring inputs to outputs. When reward is based on an outcome it becomes an incentive to do everything possible for customers and patients.

This is what ‘from volume to value’ means; a move from doing the minimum to the maximum, for patients. Nowhere do we see the move from volume to value more clearly than in the growth in the importance of RWE.

In this latest thought piece, eyeforpharma explores the power of RWE to transform the understanding of patients, treatments, outcomes and costs.  

Trends in Medical Affairs

In this magazine, we sit down with Dr Ameet Nathwani, CMO at Sanofi to discuss the burgeoning role of medical affairs and the need for continuous, cost-effective evidence generation. We explore why MSLs need to get in touch with their emotions to engage with impact and we delve into the changing face of medical affairs as it's set to become a fully-fledged strategic partner…

Aligning cost with value in oncology

In 2016 our webinar "Demonstrating Value in Price" provided discussion around a plethora of vital questions on pricing & value frameworks. In response, we've developed a paper compiling industry research, top insights for the webinar, and exclusive interviews. 

Contributors include:
 - Mike Kolodziej, National Medical Director, Aetna
- Scott Shortenhaus, Director Oncology, Professional Relations, Advocacy, & Policy, Eli Lilly
- Anna Forsythe, Head of Global Value & Access, Eisai
- Steven Paulson, CEO, Texas Oncology
- Jack Whelan, Cancer Warrior

Artificial Intelligence: A Brave New World for Pharma

Now, with the advent of ‘big data,’ companies are harnessing the power of AI to deliver more focused solutions in a variety of areas; AI helps them understand data in real-time. In a recent interview, Dr Andree Bates, President of Eularis, agreed to share some thoughts on how AI can be applied to the pharmaceutical industry to help reduce trial time, crunch data, and facilitate healing.

"We Need to Talk": Achieving Market Access in South Africa

Achieving commercial success has proven difficult due to inflexible pricing legislations, non-standard dossier requirements, unclear guidelines, and restricted formulary access by prescribers.

9 industry experts partnered with eyeforpharma to help understand the current environment and how to move healthcare in South Africa in the right direction.

The whitepaper delves into:

- The current situation between payers and pharma
- How the public and private sectors are changing
- Private v public market - does pharma really have to make a choice?
- Physician and patient perspectives
- How to build a mutually respected and valued relationship
- How pharma can regain trust with other stakeholder groups

Market Access & Pricing Excellence. Real World Evidence Europe 2015 Highlights

Market Access & Pricing Excellence 2015, co-located in Amsterdam with Real World Evidence Europe, gave key players the opportunity to discuss the future funding of innovative pharmaceuticals, approaches to incorporating real world evidence (RWE) into product development, and challenges associated with the growing body of patient data collected with the help of mobile devices. 

Download to find out what happened at this year's event.

The Voice of the Organized Customer

The Voice of the Organized Customer

Pharma’s Opportunity to Meet the Needs of Health Systems in a Shifting Healthcare Landscape

The majority of pharma’s current go to market strategies does not achieve the expected results. It is pivotal to develop and execute B2B programs based on a validated commercial effectiveness model that meets customer needs.

Are you ready to partner with health systems and IDNs?  We've partnered with The Kinetix Group and surveyed health system leaders for a new strategy briefing.

This 20-page briefing has been written to show you:

- The shifting site of care landscape with new analytics and EMR systems, the increasing role of the consumer and rapid consolidation - what does it mean for your go-to market model?
- Six detailed case studies that illustrate pharma’s opportunity to lead the change and collaborate
- What you can do through enhancement of field team credibility, population health management, patient engagement through customizable solutions, and utilizing the patient journey.

The Future of the U.S. Oncology Market: Preparing for Healthcare 2.0

This 15-page report presents cross-industry analysis on reimbursement and market access strategies designed to help you:

  • Overcome barriers to traditional premium pricing
  • Re-align stakeholder partnerships in the context of evidence-based care and clinical pathways
  • Leverage risk-sharing agreements as a mechanism of market access in the US
  • Achieve favorable reimbursement through ECV differentiation and value added services
  • Prepare for demands around companion diagnostics

Real world evidence and digital healthcare: The next frontier

This  15-page report looks at Pharma's biggest opportunities for the future, including:

  • A new frontier of innovation
  • Smartphone penetration: The power of numbers
  • The challenges of data collection and design of wearables
  • Key takeaways for Device Design
  • Looking to the future

Executive Briefing on ORAL ONCOLYTICS

The 16 page whitepaper includes:

  • Understand the realities and trade-offs for oral therapeutics

  • Strategic perspectives and pharma case examples

  • Learn about the next frontier of new agents

Market Access England: Navigate the Value Chain

Although England accounts for no more than 3% of global pharma sales, it is, alongside Germany, the most externally referenced country in Europe in relation to drug pricing. However, recent structural reforms to the NHS and NICE have complicated an already difficult market access approach.

This exclusive whitepaper aims to simplify these changes and offer you clear guidance on a new model of market access in this crucial European market.

Value-Added Services Summit 2014: Highlights Report

Partners in Integrated Healthcare: Evolving to a Solutions-Based Model.

Download this 14 page report to:

  • Find out what the trends in integrated care in European pharma are

  • Learn about how Sanofi, Janssen and MSD are doing to build value added services

Payer’s Forum Highlights eBook

Partnering with Payers to Deliver Value.

Download this 18 page eBook to gather insights from:

  • Alexander Natz, Director General, EUCOPE

  • Oriol Solà-Morales, Former Director of HTA assessment, Catalan Agency HTA

  • Thomas Schael, CEO and Commissioner, Local Health Authority, Naples

The Pharmacist: Tomorrow’s Stakeholder

As the pharmacist is becoming a more integral stakeholder in a patient’s decision making process. It is imperative that pharma companies understand the market dynamics shaping up the pharmacy industry. Cedric Pantaleon, GSK, reveals that engaging pharmacists to boost adherence to complex drug regimens is revolutionary in the pharmacy channel. The increasing pace of the change suggests that there is a demand to adjust current models.

The Accountable Care Organization

The Accountable Care Organisation is the most ambiguous of the new entities borne of the Affordable Care Act - however, an understanding of the principles of engagement with this trailblazing new institution is crucial to successful navigation of the US oncology landscape.

Emerging Markets: The Second Tier

eyeforpharma has spoken to innovative industry experts and offers you this exclusive guide to ensure permanence and sustainability in some of the fastest growing markets in the world.

Featuring business intelligence and regional insights on Indonesia, Pakistan, Ukraine, Thailand and Vietnam.

Show Me The Evidence

Payers are now a significant player in product commercialization and companies need to rethink their business models.

In this whitepaper we hear directly from G5 European Payers on there needs and expectations of the industry when bringing drugs to market.

Real World Data: Sources and Applications

Expert guidance on the benefits and sources of real world data. An overview of the disruption RWD will cause to R&D, clinical outcomes and market access.

Oncology Reimbursement

As demand rises and budgets constrict across the continent, reimbursement for Oncology drugs has become a significant challenge for European pharma. What has become clear is that developing a market access strategy on a country-by-country basis is key.

We've commissioned this paper to analyze how Germany, UK and Spain have developed, providing insightful models for your reimbursement approach across the rest of the continent.

Personalized Medicine in Oncology

Advancements in Personalized Medicine claim to deliver better efficacy, better outcomes and better value... But can personalized medicine actually deliver on this promise?

Understand the true impact of personalized medicine on your stakeholders.

What Pharma Can Learn From Patients

A Global Patient Advocate Survey

Pharma want to engage with patients, but it is still not clear when and how this should happen. The struggle to attract and retain patients to clinical trials remains one of the major challenges in the drug development process.

MK&A and eyeforpharma surveyed a range of global patient advocacy groups and you can see the results and discussion of the outcomes in this whitepaper. 

The Whitepaper contains discussions of the survey findings from;
- Jeff Sherman, CMO, Horizon Pharma
- Jeanne Regnante, Executive Director, Head, Patient engagemeent strategy office, Office of the CPO, Merck & Co, Inc
- John Whyte, Director, Professional Affairs and Stakeholder Engagement, FDA
- Jane Reese-Coulbourne, Senior Consultant, MK&A

Patient Centricity vs. Profitability - why commercial innovation is key

Beyond a few organisations where entire teams and roles have been created around the pursuit of true 'patient centricity', some of pharma's most important customer-facing functions are unclear on the necessary steps needed to be worthy of the title 'patient-centric' - and even whether or not it should be their objective at all. 

Highlights of the whitepaper include:

- Can patient-centricity and profitability co-exist? We have the answer.
- We ask industry experts about finding the 'sweet spot' where there can be both patient focus and business focus - and the needs of both are met
- Pharma have confidence in the commercial benefirts of patient focus, but lack the confidence to take thinks to the next level. We explore what is needed to make this happen.
- How to make patient focus and business focus real - throught budget, measurement, and training.
- Concrete examples of the role of patient focus on profitability. 

Key Contributors:

- Christi Shaw, former U.s. Country Head and President, Novartis Pharmaceuticals Corporation
- Ramona Sequeira, President, Takeda Pharmaceutical Company Ltd
- John Gerow, Service Team Strategy Partner, Ashfield & Principle, JG Consulting Inc.
- Deborah Waterhouse, SVP and Business Unit Head UD Primary Care, GSK
- Jens Lipinski, Head of Patient Relations, Bayer Healthcare

Patient-Centred Culture by Design

Embedding patient-centred focus into the culture of pharmaceutical organisations. 

Big pharma claim their long term goal is to embed a patient-centred culture across their organisation – but how can they undertake such a fundamental change considering their complexity, size and resistance to change?

Key topics addressed include:

- Organisational change: Reinforce new systems, align internal structures and encourage cross-collaboration
- Talent: Hire and train your workforce to adopt new behaviours, competencies and attributes
- Return on investment: identify specific KPIs to identify patient-centred results and impacts on your business

Your Customer is in Charge; Barcelona 2015 Conference Highlights

We have put together an exclusive report summarising the key takeaways from Barcelona 2015 - great to share amongst those who couldn’t join us along with those who were there. 

Take another look at how:

- Our C-suite panel reinforce a patient-centric culture with a drive for personalised healthcare and external partnerships

- VPs from BI, Merck, Ferring, CSL Behring and UCB are embedding the patient voice in their own organisation

- Digital technology is transforming the way we engage with our customers and revolutionising our sales force

- Key conclusions, critical learning and exclusive polling results from Europe’s largest commercial pharma gathering

Adjusting to a New Reality: Progressing Patient-Centricity. The Patient Summit 2015 Highlights

 
The Patient Summit conference is now in its twelfth year, and during that time
the concept of a patient-focused pharmaceutical industry has become a reality.
From a slow start as a microtrend pioneered by the more innovative companies,
the patient voice can now be heard at every step of the decision-making process. 
 
Download to find out what happened at this year's event.

How is pharma tackling non-adherence?

Non-adherence to medication causes problems for patients, healthcare providers, payers and pharma companies. It impacts Pharma by reducing revenues and undermining payer and prescriber confidence in the effectiveness of the brand. S3 group teamed up with eyeforpharma to survey over 200 healthcare professionals to study the extent and scale of the issue and to understand the initiatives, structures, objectives and practices the Pharma industry is putting in place to tackle it.

Payers’ Forum, Europe Summit, 2014, Highlights Report Partnering with Payers to Deliver Value

Download this 13 page report and learn about:

- Homogenization of HTA processes in Europe
- Value-based pricing 
- Pharmaceutical Price Regulatory Scheme 
- Putting together a perfect dossier for the German market 
- Strategy needs for centralized and decentralized countries

The Patients Summit 2014: Highlights Report - Adding colour to the picture

 
- Insights into how the Patient Opinion Leader is driving change in pharma
- Examples of what a real patient-centric organisation looks like
- Videos of interviews with key speakers including Keir Woods, Director Oncology GSK and Jack Whelan, Cancer survivor.
 

The Patient-Centered Clinical Trial (PCCT): How to Achieve the Organizational Change Needed

The 15-page whitepaper provides insight into:

  • Practical examples and executive action points to realize the PCCT in each dimension

  • Case studies from 19 senior clinical trial leaders from Eli Lilly, Genzyme, National Breast Cancer Coalition, CTTI, PCORI, UCB, Cancer Treatment Centers of America, Michael J. Fox Foundation and many others

The True Value of Telehealth

Telehealth is gathering support as a cost-effective tool to help deliver sweeping improvements in healthcare. There is much debate however as to whether it improves quality of life or isolates the patient and whether it is an affordable addition to the patient care toolbox.

The True Value of Telehealth examines the case for inclusion, honestly confronting arguements against and clarifying the measures and expectationsyou need for a successful telehealth approach to patient care.

The Patient Communication Opportunity

The opportunities for effective patient communication have never been so numerous or so important. We've put together a little guide designed to demonstrate where putting time and resources is likely to have the greatest positive impact for the patient and for the industry.

The Importance of Patient Services

It is increasingly apparent that the pharma industry has a role to play in patient support. While traditional communication efforts have been focused on increasing prescriptions, the reality is that those prescriptions are not delivering the benefits they should to patients. In return, non-adherence patients are costing the industry billions of dollars every year.

This paper focusses on the positive effect that patient services can have on adherence, to the benefit of the patient and the industry.

The Great DTC Shake-Up

This in-depth eyeforpharma whitepaper, which we developed with Health Perspectives Group explores the evolving role of DTC advertising with direct feedback from patient’s - including exclusive results from the recent “DTC Attitudes, Behaviours and Preferences” patient study conducted by Health Stories Project – Insights, (HSPi).

GSK's new 'ethical' customer approach: Is it delivering?

GSK’s move to a new model of customer engagement has generated a great deal of debate. Indeed, many commentators remain skeptical that this ‘ethical’ model – especially the decoupling of sales incentives from prescription volume isn’t robust enough to deliver results in the long-term.

Will GSK’s new transparent, reputation-boosting sales model be a template for the entire industry? 

Goodbye, sales and marketing. Hello, integrated Commercial team!

What does the future hold for commercial...?

This in-depth eyeforpharma whitepaper will explore how pharma is integrating customer-facing teams in order to become more customer-centric.

The aim? To avoid duplication and ensure consistency of approach across a number of stakeholders. 

This paper explores:
- The drivers behind these trends (the problem)
- The wider benefits of greater customer-centricity (the solution)
- How companies are changing internally to realise this vision
- The challenges of greater integration
- The roles and skillsets within integrated commercial teams
- The impact on customers
- The future of the commercial team

Patient Centricity vs. Profitability - why commercial innovation is key

Beyond a few organisations where entire teams and roles have been created around the pursuit of true 'patient centricity', some of pharma's most important customer-facing functions are unclear on the necessary steps needed to be worthy of the title 'patient-centric' - and even whether or not it should be their objective at all. 

Highlights of the whitepaper include:

- Can patient-centricity and profitability co-exist? We have the answer.
- We ask industry experts about finding the 'sweet spot' where there can be both patient focus and business focus - and the needs of both are met
- Pharma have confidence in the commercial benefirts of patient focus, but lack the confidence to take thinks to the next level. We explore what is needed to make this happen.
- How to make patient focus and business focus real - throught budget, measurement, and training.
- Concrete examples of the role of patient focus on profitability. 

Key Contributors:

- Christi Shaw, former U.s. Country Head and President, Novartis Pharmaceuticals Corporation
- Ramona Sequeira, President, Takeda Pharmaceutical Company Ltd
- John Gerow, Service Team Strategy Partner, Ashfield & Principle, JG Consulting Inc.
- Deborah Waterhouse, SVP and Business Unit Head UD Primary Care, GSK
- Jens Lipinski, Head of Patient Relations, Bayer Healthcare

Customer Experience and Beyond: Why Digital Changes Everything

We spoke to some of the most respected names in the industry, including:

- Gerhard Arnhofer, Vice President, Head of Integrated Multichannel Marketing CoE, Bayer
- Tim White, Head of Customer Experience, Teva
- Panos Papakonstantinou, Head Digital Commercial, Europe, Novartis
- Monique Levy, SVP, PatientsLikeMe
- Jessica Federer, Chief Digital Officer, Bayer
- Hicham Naim, Strategy & Customer Centricity Europe and Canada, Takeda

… to find out why pharma has been so slow in properly implementing multichannel and how we can catch up with industries such as banking, retail and airlines.

Discussing topics such as digital transformation, change management and customer experience this white paper will give you all you need to know to perfect your multichannel strategy and build stronger relationships with your key customers. 

Quality Risk-Based Management by Design

We recently sat down with Brian Nugent, Associate Director, ClinOps Process at Gilead Sciences. He shared his experience with designing a successful framework on how QbD (Quality by Design) can be integrated into the risk mitigation management model and how to realize an optimal return from RBM (Risk Based Monitoring).

Gain these insights and get your copy now

KAM Prescription for Commercial Success

As cost pressures continue to rise and the decision-making power shifts from physicians to a broader range of stakeholders, leading pharma companies are actively switching to key account management to develop lasting value partnerships with the evolving customer base.

Download eyeforpharma’s new whitepaper featuring first-hand insights from Key Account Managers at Daiichi Sankyo, Lilly USA, Pfizer, Eisai, Alcon and Shire.

Find out more about:

- New models of engagement
- The true meaning of the KAM role
- Organizational and structural implications

Artificial Intelligence: A Brave New World for Pharma

Now, with the advent of ‘big data,’ companies are harnessing the power of AI to deliver more focused solutions in a variety of areas; AI helps them understand data in real-time. In a recent interview, Dr Andree Bates, President of Eularis, agreed to share some thoughts on how AI can be applied to the pharmaceutical industry to help reduce trial time, crunch data, and facilitate healing.

Future Signs: Trends that will Shape the Future of Healthcare

"Future Signs" provides an illuminating round-up of the technologies and trends that will shape the future of healthcare.

In order to remain relevant, pharma's role will need to change to reflect the technological improvements, societal expectations and medical improvements Mesko predicts.

In this overview, you will read about:

- Some of the disruptive innovations that will allow patients to become the pilots of their own health

- The practical and ethical challenges this new technology brings e.g. healthcare will become more predictive

- The need for pharma's role to change with enhanced communication between pharma and patients becoming vital

- The need to embrace technology in order to deliver highly customized options

The 7th Era of Marketing: Content-Driven Experiences

Content is essential but the key is how this strategy can be integrated into your marketing and customer plans across the business.

This paper covers: 

- How patient experience is driving marketing and how pharma can respond

- Content is not an end in itself: understand exactly who your customers are and what they want

- Create a story with heart and instil brand consistency

 

Inspirational Leaders in CX: 3 Case Studies from the Multichannel Customer Experience Conference 2015

We have put together an exclusive report summarising the key Case Studies from Multichannel Customer Experience 2015 - great to share amongst those who couldn’t join us along with those who were there.

- Hear from three out-of-industry Customer Experience experts who share their experiences of how they instigated culture change to engage their employees and transform into highly focused, customer-oriented organisations that could deliver a highly efficient customer experience.

- Understand your audience and who you’re for. Use data to draw out fundamental needs. Invest in tools which will help you understand customer behaviour.

- Really understand what you’re for, your purpose and communicate it.

„- Reach your audience in new and unexpected ways with engaging, powerful stories that form an emotional connection.

„- Measure: keep a rigorous eye on what’s working and what’s not.

Your Customer is in Charge; Barcelona 2015 Conference Highlights

We have put together an exclusive report summarising the key takeaways from Barcelona 2015 - great to share amongst those who couldn’t join us along with those who were there. 

Take another look at how:

- Our C-suite panel reinforce a patient-centric culture with a drive for personalised healthcare and external partnerships

- VPs from BI, Merck, Ferring, CSL Behring and UCB are embedding the patient voice in their own organisation

- Digital technology is transforming the way we engage with our customers and revolutionising our sales force

- Key conclusions, critical learning and exclusive polling results from Europe’s largest commercial pharma gathering

HCPs: "We want Partnerships with Pharma"

What can pharma do to improve patient care? eyeforpharma along with M3 Europe asked 549 European healthcare providers questions provided by pharma execs.

We then analysed the results and got senior level execs from Boehringer-Ingelheim, M3 Europe and AbbVie to comment. These were some of the results:
- How pharma can help to improve patient care and support
- How HCPs would operate if they were in your shoes
- The perception HCPs have about pharma companies and why
- The thoughts of hundreds of HCPs in one place

 

Razing Silos to Enhance Collaboration

Developing an organization that drives value, wellness and integrated care

This 14 page paper will help you to:

  • Gain insights into what industry leaders such as Merck, Pfizer & GSK are doing to enhance collaboration
  • Drive more effective cross-functional collaboration through an understanding of the key ingredients for success
     

Blackdot: Bridging The Gap

Understand the critical role of the First-Line Sales Manager in Re-focusing the Frontline Sales Effort.

This whitepaper will provide insight into:

  • How performance profiling can enable better, more tailored individual management

  • How to achieve total buy-in to your segmentation, targeting, and sales model

  • Which processes drive effective communication that enable organisational clarity and high-performing sales teams

From Dinosaur to Digital: How Smart Technology is Transforming Pharma Sales

Discover the impact for your role during times of digital advancements by downloading your 18 page whitepaper.

Your copy will include:

  • 7 case studies on how digital is affecting sales

  • Insights from Actelion, MHI Global, Boehringer Ingelheim, UCB, LEO, Treato and Astellas

  • Evidence that if your company provides better customer experience you will perform better financially

Leveraging the mHealth Opportunity

  • Be inspired by 6 pioneers of mHealth and how they have developed mobile health apps

  • Gain insights into the key trends in mhealth

  • Understand how to leverage mHealth opportunities and drive value for HCPs, payers and patients

Value-Added Services Case Study Overview

A step-by-step guide to the imagination and implementation of value-added services in pharma, with case studies from Janssen Healthcare Innovation, Pfizer Integrated Health, MSD, Eli Lilly and NICE. It’s not an exact science, but our interviewees have enough real experience between them to help guide you on your way.

The Industry Healthcheck: Results

Download the results from this year's Healthcheck survey complete with commentary from industry thought leaders and find out what 1600 senior pharma executives from around the globe thought about:

  • The state of trust and reputation in the pharma industry

  • The strategic direction of the industry

  • How payers are changing the pharma sales environment

  • How pharma sees healthcare reform impacting the industry

Barcelona 2014

This 15 page report will provide you with:

  • Practical steps on how to drive digital success from Boehringer Ingelheim

  • Insights from UCB on how to transform into a patient-centric organisation

  • Foresight into how the changing payment model will impact your business from RAND

  • An example of how Pfizer US moved from volume to value

Multichannel: Time for Implementation

How to overcome the biggest challenges that hinder multichannel marketing implementation.

  • What you need to get your team and the organisation up to speed for implementation success

  • Practical steps on how to gain the support from leaders and functions including IT, communications and sales

  • Insights from experts on what you need to do to ensure compliance and how to develop the right approval process

Give Your Mobile App A Clean Bill Of Health

As the marketplace floods with medical apps for mobile devices, bringing patients directly in contact with app developers who may not be accustomed to handling sensitive health information. In addition to the fast growing number of savvy app users and perceptive authorities, it is becoming crucial that you ensure that your mobile app is in line with data protection best practice.

Implementing CLM

The benefits of CLM are numerous and well known, however there's one topic rarely touched upon - once you've made the decision to go CLM, how do you implement it?

Innovation: From Concept to Reality

In today's world of technological marvels, it's never been a better time to be a pioneer, a disruptor, an innovator. However despite our 21st century appetite for pushing boundaries, it's often still a challenge to grow and nurture these ideas in established companies.

Featuring interviews and insights from some of the industry's most creative marketers, our constructive guide will help YOU sell your innovative idea!

Sales Best Practice

Of all the business functions in pharma, sales are perhaps experiencing the greatest change.

Discover what practices your sales teams need to be employing and the latest sales management techniques being used by industry leaders in our comprehensive guide.

Welcome to our Premium Plus+ Reports. Log in, Subscribe or Buy Now, to access eyeforpharma's most up-to-date research.
Need help? Contact Aleksandra today.

The Role of the Sales Representative in a Multichannel World 2015

Published: December 2015

Advancing Multichannel Customer Engagement in Pharma

- Understand how the role of the sales representative and the face-to-face meeting is evolving.

- What are the implications on the organization and commercial approach with the changing role of the sales representative.

- What are the talents, capabilities, structure and resources that are needed for new sales representative role?

- Understand how your future commercial model can answer to the increased complexity of healthcare and what role your sales representative should play.


€2935 / US$3225 FREE for Premium Plus+ and Enterprise Subscribers

Currency conversions £2160 : CA$4031


For more information contact Aleksandra

View Report Subscribe Buy Now
Pharma Marketing Data Infrastructure 2015

Published: July 2015

Handle the data your marketing needs.

- Understand how to build a data infrastructure that support your desired marketing capabilities.
- How to roll out without business interruptions.
- Insights to the what, who, why and how of data management.
- Take the next steps in analytics and be customized, predictive and automated.


€2935 / US$3225 FREE for Premium Plus+ and Enterprise Subscribers

Currency conversions £2160 : CA$4031


For more information contact Aleksandra

View Report Subscribe Buy Now
Customer Experience Management 2015

Put the customer at the centre of your strategy, organization and capabilities.

- Learn what Customer Experience means for your company and how to align it with your commercial strategy.
- Understand how to structure your organization around the customer in practical steps.
- Make it work with real cases of adapting processes to customer centricity.


€2935 / US$3225 FREE for Premium Plus+ and Enterprise Subscribers

Currency conversions £2160 : CA$4031


For more information contact Aleksandra

View Report Subscribe Buy Now
Value Added Services 2015

3 tailored roadmap's to solutions in healthcare beyond the pill.

- Understand the creation of successful services by looking at organizational structure and internal processes, how to partner with external stakeholders, and how to make projects economically viable.
- A roadmap tailored to your company with three scenarios for creation, development, implementation and up-scaling of ‘Value Added Services’.
- In-depth case studies of company-wide initiatives and specific projects, such as Janssen Healthcare Innovation, Sanofi Integrated Care, Pfizer Integrated Health, Grunenthal´s ‘My pain feels like’ and Boehringer-Ingelheim´s ‘Picasso’.


€2935 / US$3225 FREE for Premium Plus+ and Enterprise Subscribers

Currency conversions £2160 : CA$4031


For more information contact Aleksandra

View Report Subscribe Buy Now
Key Customer Engagement 2015

Published: September 2015

A guide of best practices to developing strategy, organization, human resources and tools for Key Account Management in pharma that will yield positive business results, strengthen customer relations, and take the company into future.

- Build a solid case for customer engagement success with insights from the most advanced companies in the industry

- Understand how your future commercial model can answer to the increased complexity of healthcare by being flexible, versatile, and adaptive

- Manage internal stakeholders and leadership teams to drive cultural, strategic, and organizational change needed for successful key account management

- Learn best-practices for KAM implementation and operation: customer mapping and prioritization, value creation, organizational structure, performance metrics, and training
 


€2935 / US$3225 FREE for Premium Plus+ and Enterprise Subscribers

Currency conversions £2160 : CA$4031


For more information contact Aleksandra

View Report Subscribe Buy Now
Multichannel Marketing Business Case Report 2014

Understand how to keep up your multichannel marketing strategy with the dynamic stakeholders.

- Case studies from industry leaders on how they are developing their multichannel strategies.
- Identifying stakeholder needs and how pharma companies can gain commercial leverage.
- Critical success factors: What can be done to shift over to a multichannel marketing mentality.


€2935 / US$3225 FREE for Premium Plus+ and Enterprise Subscribers

Currency conversions £2160 : CA$4031


For more information contact Aleksandra

View Report Subscribe Buy Now
Innovative Sales Strategies & Metrics Report 2014

Cutting edge sales strategies and metrics to future proof your salesforce

- Discover innovative sales strategies you can implement in 2014 to improve your sales performance.
- Transform your incentivization structure to drive customer-centric behaviours that impacts your bottom line.
- Examples from FMCG on successful sales models relevant to pharma.


€2935 / US$3225 FREE for Premium Plus+ and Enterprise Subscribers

Currency conversions £2160 : CA$4031


For more information contact Aleksandra

View Report Subscribe Buy Now
Value Added Services Report 2013-2014

Prepare your organisation for the future with 'Beyond the Pill' services

- Redefine your business model: A step-by-step guide in order for your company to truly redefine the way you operate so services can be fully integrated.
- Case Studies from the leaders: We look at real examples from Janssen Connect, AstraZeneca, GSK and Fresenius Medical Care.
- 360 degree view of value added services: Detailed interviews with all stakeholders, pharma, payors, physicians, regulators and patient advocacy groups


€2935 / US$3225 FREE for Premium Plus+ and Enterprise Subscribers

Currency conversions £2160 : CA$4031


For more information contact Aleksandra

View Report Subscribe Buy Now
Growth Markets Report 2013-2014

Capitalize on new market opportunities and develop a robust business strategy. Strategic market intelligence on China, Brazil, Mexico, Thailand, Indonesia, Venezuela.

- A detailed overview of each market including success and failure secrets
- Develop a winning strategy based on exclusive insight from our 50 industry contributors and exclusive survey
- Anticipate regulatory changes to get ahead of your competition
- Up-to-date insight on the best opportunity for pharma to grow over the next 24 months.


€2935 / US$3225 FREE for Premium Plus+ and Enterprise Subscribers

Currency conversions £2160 : CA$4031


For more information contact Aleksandra

View Report Subscribe Buy Now

Welcome to our Archived Reports. Log in, Subscribe or Buy Now, to access our On Demand research.
Please contact Aleksandra today for more information on how to gain access to the very latest eyeforpharma research.

Real World Data Report 2013

Understanding how real world data is developing the pharmaceutical industry’s business model.

- The best sources of RWD - What makes these sources the best and for which purpose.
- Case studies and detailed discussions from industry leaders highlighting their priorities going forward and how RWD is affecting their roles.
- Payor needs - What do pharma need to do in order to satisfy the payor and achieve reimbursement.


€2935 / US$3225 FREE for Premium Plus+ and Enterprise Subscribers

Currency conversions £2160 : CA$4031


For more information contact Aleksandra

View Report Subscribe Buy Now
Multichannel Marketing Report 2013

Use the resources you have today to integrate more successful digital and mobile channels into your marketing

- What information is important to the customer - What content, at what frequency and which channels are most important to them.
- Channel integration - How to create a consistent message across all channels, showcasing the most effective channels through ROI and KPIs.
- Advancement of future channels - Mobile and the investments being made by competitors into researching and improving this area.


€2935 / US$3225 FREE for Premium Plus+ and Enterprise Subscribers

Currency conversions £2160 : CA$4031


For more information contact Aleksandra

View Report Subscribe Buy Now
Multichannel Marketing Latin America Report 2013

Improve your marketing mix – an analysis of the digital, mobile and social media landscape: boosting engagement, brand awareness, sales and patient knowledge.

- 51 exclusive interviews and 10 case studies in Latin America, Europe and North American regions on digital initiatives to learn from.

- 20+ Figures/charts/tables, reflecting primary research and the most up-to date secondary data available.

- An analysis of the digital, mobile and social media landscape to improve your marketing mix: boosting brand awareness, sales and patient knowledge.


€2935 / US$3225 FREE for Premium Plus+ and Enterprise Subscribers

Currency conversions £2160 : CA$4031


For more information contact Aleksandra

View Report Subscribe Buy Now
Pharma e-Marketing Report 2011/12

An analysis of the mobile and digital landscape to improve your marketing mix and boosting brand awareness.

- Comprehensive analysis on the digital footprints of patients and physicians.
- Analysis of the digital landscape currently in mobile, web, tablet computing and social media.
- Expert opinions on the future eMarketing and the anticipated regulatory context.
- 30 case studies on digital initiatives to learn from.
- Data from pharma/medical device executives on their expected digital budget 2012-16, eMarketing priorities and who they see as leading the way in digital.


€2935 / US$3225 FREE for Premium Plus+ and Enterprise Subscribers

Currency conversions £2160 : CA$4031


For more information contact Aleksandra

View Report Subscribe Buy Now
Pharma Key Account Management Report 2011/12

How to revolutionise your KAM strategy to increase profitability.

- Expert overview of KAM's commercial effectiveness, patient adherence, sales force numbers and account planning.
- Thorough Analysis of the different selling methods for value proposition, including toolbox versus clean-sheet approach.
- Examples of KAM best practice for pharma, advice on how to measure ROI including; direction, impact, progress, tactic, value and overall results.
-The key steps when transitioning to KAM, including the cultural and practical challenges.


€2935 / US$3225 FREE for Premium Plus+ and Enterprise Subscribers

Currency conversions £2160 : CA$4031


For more information contact Aleksandra

View Report Subscribe Buy Now